hotspot -WSS

hotspot

author：hotspot 2025-09-28 23:49:27 - browse：73

insulin biosimilar — The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. Jacquelyn Martin/AP

A group representing clinical labs across the country sued the Food and Drug Administration on Wednesday over the agency’s plan to actively regulate lab-developed tests.

The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. When the FDA finalized its test regulation plan last month, several experts said it was only a matter of time until someone in the lab industry sued.

Tests made in labs have historically gone unregulated by the FDA, as the agency considered them low-risk when it started regulating medical devices in 1976. But the tests have since become more numerous and complex, and the regulatory gray area enabled unreliable tests to thrive and harm patients. Infamous examples include Theranos’ blood tests, as well as misleading prenatal genetic tests from a range of companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

WSS

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Caregivers of transplant patients call for more support, training

New menopause drug shows promise in relief for hot flashes

New England Journal of Medicine addresses racist history, slavery

Biden administration begins canceling student loan debt for 804,000 borrowers

Judge sides with young activists in first

explore

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

hotspot

Sports medicine is finally prioritizing gender equality

DeSantis can now import cheaper drugs. But will Biden get credit?

Walensky prepares to leave CDC — and Congress — behind

BMS, looking to build heart drug business, turns to AI for diagnosis

Duchenne breakthrough therapy leaves behind pioneering families

Illumina slashes 2023 revenue projections yet again

Virginia high school admissions case could be legal follow

Judge sides with young activists in first

Medical records are filled with copy

DeSantis can now import cheaper drugs. But will Biden get credit?

focus

DeSantis can now import cheaper drugs. But will Biden get credit?

DeSantis can now import cheaper drugs. But will Biden get credit?

Schizophrenia gene found to be linked to cells' energy dysfunction

Surge in Apellis stock fueled by confidence in safety of its eye drug

Hospitals are dialing back on venture capital investing

Megan Rapinoe shares emotional post following US Women's World Cup exit

focus

focus

focus

Wikipedia